Departmental Unit of Gynecologic Oncology, Department of Procreative Medicine, University of Pisa, Italy.
Best Pract Res Clin Obstet Gynaecol. 2011 Dec;25(6):783-95. doi: 10.1016/j.bpobgyn.2011.06.002. Epub 2011 Jul 18.
Uterine sarcomas usually have an aggressive clinical behaviour, with great tendency to local and distant spread, with unfavourable clinical outcome, excluding endometrial stromal sarcomas and adenosarcoma. Tumour stage is the strongest prognostic factor for all uterine sarcomas, with 5-year survival of about 50-55% for stage I and 8-12% for more advanced stages. Multivariate analysis of some studies have shown that women with leiomyosarcoma have a poorer survival than those with carcinosarcoma. The key issues that will be discussed include the prognostic relevance of pathological and biological variables other than tumour stage in the different histological subtypes of uterine sarcoma. Immunomarkers for cell proliferation and apoptosis have been tested for the identification of tumours with different clinical behaviour, but they are still subject to research and are not currently used in clinical practice.
子宫肉瘤通常具有侵袭性的临床行为,具有很大的局部和远处扩散倾向,临床结局不佳,除了子宫内膜间质肉瘤和腺肉瘤。肿瘤分期是所有子宫肉瘤的最强预后因素,I 期的 5 年生存率约为 50-55%,而更晚期的生存率为 8-12%。一些研究的多变量分析表明,平滑肌肉瘤患者的生存率比癌肉瘤患者差。将讨论的关键问题包括肿瘤分期以外的病理和生物学变量对不同组织学亚型子宫肉瘤的预后相关性。细胞增殖和凋亡的免疫标志物已被用于鉴定具有不同临床行为的肿瘤,但它们仍在研究中,目前尚未在临床实践中应用。